Biocancell Releases Results From Cancer Drug Trial

Israel’s Biocancell Therapeutics reported successful results of a trial of its BC-819 treatment for ovarian cancer.

The company reported a 50 percent reduction in the protein marker indicating the presence of ovarian cancer and a significant decline in the number of cancer cells in patients, Israeli business daily Globes reported.

BC-819 is intended for those in whom other ovarian cancer treatments have failed and also is intended to treat liver, bladder and spleen cancer.